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TREATMENT PATTERNS OF PATIENTS WITH METASTATIC BREAST 
CANCER AFTER FAILURE TO ANTHRACYCLINE AND TAXANE UNDER 
THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Serrano SV1, Nita M2, Teich V3, Litalien G4, Teich N3, Rached R2, Donato BM5, Rahal E2
1Hospital de Cancer de Barretos, Barretos, SP, Brazil, 2Bristol-Myers Squibb S/A, São Paulo, 
São Paulo, Brazil, 3MedInsight, Rio de Janeiro, Brazil, 4Bristol-Myers Squibb Pharmaceutical, 
Wallingford, CT, USA, 5Bristol-Myers Squibb, Wallingford, CT, USA
OBJECTIVES: To identify current treatment patterns of care for patients with meta-
static breast cancer (MBC), refractory to anthracyclines and taxanes, treated under the 
perspective of the Brazilian public health care system. METHODS: A cross-sectional 
study of patients from 4 public hospitals in south and southeast region of Brazil. All 
patients q18 years diagnosed with MBC who had progressed following treatment with 
an anthracycline and a taxane between 2003 and 2006, with at least 4 months of survival 
after metastatics disease were included. Data was collected from their medical charts. 
RESULTS: 217 patients with an average age of 52 years (25–80 years old) were included 
in the analysis. Among patients with HER2 testing (59%), 40% were HER-2 positive 
and among patients with hormone receptor testing (89%), 51% were hormone receptor 
positive. 85% of the patients had information regarding treatments received in their 
medical charts. The most frequent chemotherapy regimens prescribed following use of 
anthracycline and taxane (“ﬁrst line”) were capecitabine (52.7%), gemcitabine  cispla-
tin (17.4%), and tamoxifen (8.7%). Second line treatment was prescribed for 58% of 
patients: gemcitabine  cisplatin (23.4%), capecitabine (20.6%), vinorelbine (14.0%), 
tamoxifen (12.1%), paclitaxel (4.7%) and letrozol (4.7%). The median number of treat-
ment regimens was 2, with a range of 1 to 6. The average resources utilization 
per patient/year included 1.85 plain thorax x-rays, 0.57 thorax CTs, 1.06 abdominal 
ultra-sounds, 0.46 abdominal CTs and 0.86 bone scintigraphies. The average survival 
of patients after ﬁrst breast cancer diagnosis was 44.8 months (SD: 35.8; median: 32.0) 
and after ﬁrst diagnosis of metastasis was 22.4 months (SD: 20.0; median: 16.1). The 
average survival post progression to anthracyclines and taxanes was 12.7 months 
(SD: 12.4; median: 8.4). CONCLUSIONS: Within the Brazilian public health care 
system, the most frequently used ﬁrst and second line treatments, for MBC.
CARDIOVASCULAR DISORDERS – Clinical Outcomes Studies
PCV1
PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-
ADMINISTRATION OF FENOFIBRIC ACID AND LOW- OR MODERATE-
DOSE STATINS IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA
Webb SF, Simko RJ
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To estimate predicted 3-year total CVE rates (per 1000) in Hispanic 
patients with mixed dyslipidemia treated with fenoﬁbric acid and a statin compared to 
statin monotherapy. METHODS: A disease outcomes model was used to predict 3-year 
total CVE rates (per 1000) using baseline lipid, and lipid efﬁcacy, data of Hispanic 
patients with mixed dyslipidemia from a pooled analysis of three large, double-blind, 
Phase III, randomized controlled trials that evaluated the efﬁcacy and safety of fenoﬁbric 
acid 135 mg combined with low-dose statin (LDS) (simvastatin 20 mg, rosuvastatin 
10 mg, atorvastatin 20 mg) or moderate-dose statin (MDS) (simvastatin 40 mg, rosuv-
astatin 20 mg, atorvastatin 40 mg) compared to equivalent dose statin monotherapy. 
Risk for primary and secondary CVE including myocardial infarction (MI), angina 
pectoris, and stroke were based on published risk equations from the Framingham 
Heart Study. Additional risk attributable to elevated TG levels is estimated using hazard 
ratios from the Copenhagen Heart Study. RESULTS: Co-administration of fenoﬁbric 
acid and LDS or MDS was predicted to reduce 3-year total CVE rates by 37% (from 33 
to 21 per 1000) and 22% (from 31 to 24 per 1000) compared to LDS and MDS mono-
therapy, respectively. The majority of CVE were attributable to MI, followed by angina 
and stroke in all treatment groups. CONCLUSIONS: These data suggest that the co-
administration of fenoﬁbric acid and LDS or MDS may result in a 37% and 22% 
reduction in 3-year total CVE rates in Hispanic patients with mixed dyslipidemia.
PCV2
PREDICTED OPTIMAL LIPID VALUE ATTAINMENT RATES WITH THE 
CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN 
COMPARED TO STATIN MONOTHERAPY IN HISPANIC PATIENTS 
WITH MIXED DYSLIPIDEMIA
Webb SF, Simko RJ
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To predict multiple OLV attainment rates (per 1000) with the co-
administration of fenoﬁbric acid and low-dose statin (LDS) or moderate-dose statin 
(MDS) compared to equivalent dose statin monotherapy in Hispanic patients with 
mixed dyslipidemia. METHODS: A dyslipidemia outcomes model was used to predict 
multiple OLV attainment rates (deﬁned as achieving any of 3 of 4 targets: total-C, 
LDL-C, HDL-C, or TG) among a cohort of 1000 Hispanic patients with mixed dys-
lipidemia. The model simulates baseline lipid values to reﬂect natural co-variation 
using data from the National Health and Nutrition Examination Survey (1999–2004), 
simulates post-treatment improvements to reﬂect the lipid efﬁcacy of each treatment 
comparator, and then compares post-treatment improvements to US guideline-based 
lipid targets (LDL-C  100 mg/dL, TG  150 mg/dL, total-C  200 mg/dL; HDL-C  
40 mg/dL). Baseline lipid and lipid efﬁcacy data for the Hispanic population were 
from a pooled analysis of three large, double-blind, Phase III, randomized controlled 
trials evaluating the efﬁcacy and safety of fenoﬁbric acid combined with LDS or MDS 
as compared to statin monotherapy at equivalent doses. RESULTS: Compared to 
statin monotherapy, co-administration of fenoﬁbric acid with LDS and MDS is pre-
dicted to increase multiple OLV attainment rates by 63% (546 to 890 per 1000) and 
18% (630 to 745 per 1000), respectively. Fenoﬁbric acid, when co-administered with 
a statin, is predicted to result in higher proportions of patients achieving individual 
TG and HDL-C target levels; while statin monotherapy treatment is predicted to result 
in higher proportions of patients achieving LDL-C targets. CONCLUSIONS: These 
data suggest that co-administration of fenoﬁbric acid and LDS or MDS may enable 
more patients to achieve multiple OLV compared to statin monotherapy in Hispanic 
patients with mixed dyslipidemia.
PCV3
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND RISK FOR MAJOR 
CARDIOVASCULAR EVENTS IN MEN AND WOMEN
Webb SF, Simko RJ, Laitinen D, Manthena S
Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVOS: Evaluar la relación entre los niveles de HDL-C y el riesgo de eventos 
cardiovasculares mayores (ECVM) como desenlace compuesto incluyendo infarto del 
miocardio, angina, accidente cerebrovascular, y revascularizacion coronaria. MET-
ODOLOGÍAS: Análisis de cohorte restrospectivo de paraclínicos registrados la base de 
datos Ingenix LabRx. Se incluyeron pacientes con edad q50 años y perﬁl lipidico com-
pleto (fecha índice) entre el 1 de enero de 2000 y el 31 de diciembre de 2003. Todos los 
sujetos fueron enrolados en los 6 meses, antes del perﬁl lipidico y 12 meses después, ter-
minando el seguimiento cuando se presentara un ECVM o terminara su plan de salud. 
Modelos de regressión Cox fueron utilizados para evaluar el riesgo de presenter ECVM, 
controlando por ECVM previos y otros factores de riesgo cardiovascular. Hazard ratios 
(HR) multifactoriales fueron ajustados para ECVM con base en las categorías de HDL-
C: 46–50 mg/dL, 40–45 mg/dL y  40 mg/dL versus HDL-C  50 mg/dL y HDL-C: 
36–40 mg/dL, 30–35 mg/dL y  30 mg/DL versus HDL-C  40 mg/dL en mujeres y 
hombres, respectivamente. RESULTADOS: Un total de 255,953 pacientes cumplieron 
los criterios de inclusión; la mayoria (52%) fueron mujeres. En general, el riesgo de un 
ECVM se incrementó con cada 5 mg/dL de disminución en los niveles de HDL-C. Entre 
las mujeres, el HR para cada categoría fue de: 1.24 (95% IC, 1.16 a 1.34), 1.32 (95% 
IC, 1.23 a 1.41), y 1.51 (95% IC, 1.40 a 1.64). Entre los hombres los HR fueron: 1.22 
(95% IC, 1.16 a 1.28), 1.33 (95% IC, 1.26 a 1.40), 1.57 (95% IC, 1.44 a 1.70). CON-
CLUSIONES: En esta cohorte de población general, la categoría de HDL-C más baja 
se asoció con un incremento en el riesgo de un ECVM de un 51% y 57% en mujeres 
y hombres, respectivamente, comparado con la categoría de HDL-C más alta.
PCV4
COST AND OUTCOME ANALYSIS COMPARING PTCA & CABG IN LOW 
AND HIGH RISK PATIENTS
Singh S1, Malhotra S2, Tiwari P3
1Natl Instt of Pharm Edu & Res (NIPER), SAS Nagar, SAS NAGAR, India, 2Fortis Heart and 
Multispeciality Centre, SAS Nagar, India, 3Natl Instt of Pharm Edu & Res (NIPER), SAS 
Nagar, SAS Nagar, India
OBJECTIVES: The study was conducted at a private tertiary care hospital with the 
objective of performing a cost and outcome analysis of low and high risk patients who 
had undergone PTCA (n  148; 58.96%) and CABG (n  103; 41.03%). METHODS: 
Parameters like length of stay, post surgical survival, post surgical complications, read-
missions were assessed. RESULTS: The average length of stay for low and high risk 
patients who had undergone PTCA was 3.61 and 3.87 days, respectively and in case of 
CABG it was 10.94 and 10.31 days, respectively. The readmissions for PTCA patients 
within 1 year was 34 (22.97%) and only 5 (4.85%) for CABG patients. The average 
cost for low and high risk patients in PTCA was INR2,30,000/- and INR2,87,000/- 
respectively, and INR2,00,000/- and INR2,30,000/- in case of CABG. The average cost 
for PTCA (readmissions) with a follow up of 1 year was INR4,22,000/-. The results 
showed that CABG had a higher beneﬁt-to-cost ratio (0.53) as compared to PTCA 
(0.21). PTCA was associated with shorter hospital stay and mortality (2.85%) when 
compared to CABG (7.84%). CONCLUSIONS: The differences between PTCA and 
CABG for both low and high risk patients in cost, survival rate and quality of life were 
matching but 1 year follow up showed that recurrent procedures were required in case 
of PTCA. The results of this limited study need to be extrapolated in a very cautious 
manner. A selected set of patients are recommended for PTCA who require coronary 
intervention and there are reports showing that PTCA had better survival than CABG 
in patients with single vessel coronary artery diseases (CAD); whereas, CABG produced 
better survival than did PTCA in patients with severe, triple vessel CAD.
CARDIOVASCULAR DISORDERS – Cost Studies
PCV5
PROPHYLAXIS OF HEART TRANSPLANTATION REJECTION: 
FINANCIAL IMPACT ANALYSIS BY BRAZILIAN PUBLIC HEALTH CARE 
SYSTEM AND A REVIEW OF ECONOMIC EVALUATIONS STUDIES OF 
EVEROLIMUS, MMF (MYCOPHENOLATE MOFETIL) AND AZATHIOPRINE
Suzuki C1, Navarro J2, Prismich G1, Vincze G3, Machnicki G3
1Novartis Biociências S/A, São Paulo, Brazil, 2Novartis Farmacêutica S.A, São Paulo, Brazil, 
3Novartis Pharma AG, Basel, Switzerland
OBJECTIVES: To analyze the ﬁnancial impact of reimbursing everolimus, azathio-
prine and MMF in heart transplantation by Brazilian Ministry of Health. To review 
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economic evaluations studies published to date regarding these three drugs. 
METHODS: The economic impact was determined comparing the annual costs with 
drug and adjuvant therapy. The prices established by government for these drugs in 
renal transplantation were considered. Leaﬂet’s recommendations were followed for 
everolimus and MMF dosages. The dosage of azathioprine was based on clinical trials. 
The average cyclosporine dosages were taken according to the respective treatment 
available in clinical trials. Cochrane, Pubmed and Medline databases were used for 
pharmacoeconomic studies research. RESULTS: The most cost-saving therapy was 
found to be azathioprine, followed by everolimus, with the incremental annual cost 
of US$2862.81 (R$ 2.27/USD 1.00) compared to azathioprine. The third is MMF, 
showing US$704.69 of incremental cost compared to everolimus. According to the 
reviewed economic studies, everolimus is the most effective for the prevention/
stabilization of CAV (cardiac allograft vasculopathy) and is associated with economic 
beneﬁts due to its association with reduced hospitalization days due to Major Acute 
Cardiac Events (MACE). Both everolimus and MMF are more cost-effective than 
azathioprine in the ﬁrst 6 months after heart transplantation, with everolimus present-
ing a more favorable ratio than MMF. CONCLUSIONS: Azathioprine is the cheapest 
drug for prophylaxis of cardiac transplant rejection. However there are important 
economic studies assessing the cost beneﬁt of treatment outcome that have to be con-
sidered. One of the most important aspect is the effectiveness of preventing CAV, the 
major cause of late morbity and mortality following heart transplantation. To date, 
re-transplantation remains the only deﬁnite treatment for severe CAV, but there are 
ethical, cost concerns and poorer outcomes compared to primary transplantation that 
appear to be hurdles to re-transplantation.
PCV6
IMPACTO ECONÔMICO DA INCORPORAÇÃO DO TESTE RÁPIDO PARA 
DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA, SOB A PERSPECTIVA 
DO PAGADOR PRIVADO NO BRASIL
Nasciben VD, Machado F
Johnson & Johnson Medical Brasil, São Paulo, SP, Brazil
OBJETIVOS: Avaliar o impacto econômico da incorporação do teste rápido para 
diagnóstico da insuﬁciência cardíaca (IC) em pacientes admitidos com dispnéia aguda 
em pronto atendimento. MÉTODOS: Foi desenvolvido um modelo de decisão para 
projetar os custos do diagnóstico diferencial clínico e laboratorial da IC, em pacientes 
com dispnéia aguda, no Brasil, sob a perspectiva do pagador privado, considerando 
a diretrizes locais de avaliação econômica (VIANNA, 2008). O estudo foi baseado 
nos dados clínicos publicados por JANUZZI 2005, BAGGISH 2004 e DOUST 2005, 
mostrando a importância do peptídeo natriurético B (proBNP) como marcador diag-
nóstico da IC. Os dados de custos de exames clínicos e laboratoriais, ecocardiogramas, 
taxas de sala e honorários médicos foram obtidos de fontes publicas (CBHPM 4a 
edição, PROAHSA). O horizonte de análise foi de 60 dias e nenhuma taxa de desconto 
foi adotada. Uma análise de sensibilidade univariada foi conduzida para veriﬁcar se 
os resultados eram robustos. RESULTADOS: A inclusão do teste rápido de proBNP, 
para diagnóstico da IC, proporcionou redução de 58.2% na utilização de ecocardio-
gramas, 12.6% no número de hospitalizações para esclarecimentos diagnósticos. A 
utilização do teste rápido proBNP gerou uma economia de R$ 356–10%, (custo total 
de R$ 3136 para o grupo de pacientes diagnosticados com o teste rápido e de R$ 
3493 para o grupo que utilizou-se do diagnóstico clínico). CONCLUSÕES: Os resul-
tados sugerem o marcador proBNP como uma alternativa segura e eﬁcaz no diag-
nóstico diferencial da IC, quando comparado ao diagnóstico clínico, podendo trazer 
economia de recursos para o pagador privado.
PCV7
IMPACTO ECONÔMICO DA INCORPORAÇÃO DO TESTE RÁPIDO  
PARA DIAGNÓSTICO DE INSUFICIÊNCIA CARDÍACA (IC), SOB A 
PERSPECTIVA DO SISTEMA UNICO DE SAUDE (SUS), NO BRASIL
Nasciben VD, Machado F
Johnson & Johnson Medical Brasil, São Paulo, SP, Brazil
OBJETIVOS: Avaliar o impacto econômico da incorporação do teste rápido para 
diagnóstico da insuﬁciência cardíaca (IC) em pacientes admitidos com dispnéia aguda 
em pronto atendimento. MÉTODOS: Foi desenvolvido um modelo de decisão para 
projetar os custos do diagnóstico diferencial clínico e laboratorial da IC, em pacientes 
com dispnéia aguda, no Brasil, sob a perspectiva do pagador público, considerando a 
diretrizes locais de avaliação econômica (VIANNA, 2008). O estudo foi baseado nos 
dados clínicos publicados por JANUZZI 2005, BAGGISH 2004 e DOUST 2005, 
mostrando a importância do peptídeo natriurético B (proBNP) como marcador diag-
nóstico da IC. Os dados de custos de exames clínicos e laboratoriais, ecocardiogramas, 
taxas de sala e honorários médicos foram obtidos de fontes públicas (SAI/SUS e 
DATASUS). O horizonte de análise foi de 60 dias e nenhuma taxa de desconto foi 
adotada. Uma análise de sensibilidade univariada foi conduzida para veriﬁcar se os 
resultados eram robustos. RESULTADOS: A inclusão do teste rápido de proBNP, 
para diagnóstico da IC, proporcionou redução de 58.2% na utilização de ecocardio-
gramas, 12.6% no número de hospitalizações para esclarecimentos diagnósticos. O 
custo total por paciente para o grupo que utilizou o teste rápido proBNP foi de R$ 
652.04 e de R$ 659.53 para o grupo que utilizou-se do diagnóstico clínico da IC. 
CONCLUSÕES: Os resultados sugerem o marcador proBNP como uma alternativa 
segura e eﬁcaz no diagnóstico diferencial da IC, quando comparado ao diagnóstico 
clínico, podendo trazer economia de recursos para o SUS.
PCV8
COST OF ILLNESS IN PATIENTS WITH PULMONARY EMBOLISM  
AFTER ELECTIVE TOTAL HIP REPLACEMENT
Lukac M1, Bielik J2, Foltán V3, Tomek D4, Zatko D5
1Faculty of Public Health at Slovak Medical University, Bratislava, Slovak Republic, 2Trencin 
University, Trencin, Slovak Republic, 3Comenius University, Bratislava, Slovak Republic, 
4Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 5General Health 
Insurance, Bratislava, Slovak Republic
OBJECTIVES: The main objective of this analysis was to determine direct medical 
costs for pulmonary embolism (PE) in patient undergoing elective total hip replace-
ment (THR) in Slovakia from the payer perspective in 2007. METHODS: A retrospec-
tive cost of illness analysis of PE in patients undergoing elective THR during 2007 
was realized from the health insurance company perspective. Data for used resources 
and respective costs were collected from the database of the biggest health insurance 
company in Slovakia. Costs in Euro were calculated with ofﬁcial exchange rate 30,126 
Sk/a Comparison of costs between group of patients with PE and group without PE 
was done. RESULTS: The group of 2153 patients (845 men and 1 308 women) with 
elective THR was analyzed. The average age was 64.5 years (63.3 in men and 65.2 
in women). Within this group there were 11 cases of PE (average age 66.4). Average 
direct medical costs for group of patients WITH and WITHOUT pulmonary embolism 
were a2513 and a1579 respectively, with the following structure of costs: inpatient—
a2167 and a1265; drugs—a79 and 1a16; examinations and treatments during 
 inpatient stay (SVALZ)—a198 and a131; outpatient—a69 and a67 respectively. 
CONCLUSIONS: Average direct medical costs for patients with PE after elective THR 
are a2513. This is almost 60% more then the average direct medical costs for patients 
without PE. Main driver of increased costs is inpatient stay at intensive care unit and 
at internal medicine department after episode of pulmonary embolism.
PCV9
AVALIAÇÃO DO PERFIL EPIDEMIOLÓGICO E DE PRESCRIÇÃO PARA 
PACIENTES AMBULATORIAIS MEDICADOS COM ANTI-HIPERTENSIVOS
Wadt M1, Zanini AC2
1Universidade Paulista, Valinhos, São Paulo, Brazil, 2Faculdade de Medicina, São Paulo, Brazil
OBJETIVOS: Avaliar o perﬁl epidemiológico de medicamentos prescritos para paci-
entes ambulatoriais com hipertensão arterial sistêmica (HAS). MÉTODOS: Em popu-
lação com acesso à medicina complementar e benefício medicamento através de um 
PBM foi feito análise retrospectiva do consumo entre 2003 e 2008. Apenas para o 
ano de 2008, foi feita análise utilizando dados de 13.114 usuários. Os pacientes foram 
agrupados por nível de adesão ao tratamento em função do registro mensal de 
aquisições; usuários com aquisições em pelo menos 10 meses no ano foram consid-
erados para avaliação de uso e de co-morbidades. Foram adotadas as referências de 
DDD (dose diária deﬁnida) preconizadas pelo ATC-Index. RESULTADOS: O perﬁl 
de consumo ao longo de cinco anos aponta forte tendência de uso de bloqueadores 
de receptores de angiotensina II e de produtos com associação de fármacos. A comer-
cialização dos medicamentos amostrados pela PBM variou 14,7% no período, 
enquanto o INPC foi e 20,1%, e menor que outros índices do setor saúde. No que 
diz respeito ao perﬁl epidemiológico, observou-se alta adesão (10, 11 ou 12 meses no 
ano) em 9,0% dos usuários, e a adesão mediana (7, 8 e 9 meses no ano) por 9.5%. 
A maioria, de 81.5% adquiriu medicamentos por 6 meses ou menos. No grupo com 
alta adesão, 1,184 pacientes (51.6%) apresentaram co-morbidade com hiperlipide-
demia e/ou diabetes melitos; destes e 168 (14.2%) consumiram medicamentos para as 
três patologias. Em média, o grupo consumiu 2.2 DDD, 2.1 entre mulheres e 2.3 entre 
homens, ao custo diário médio de R$ 1.91. CONCLUSÕES: Em pacientes hipertensos, 
dos quais 611 medicados para co-morbidades, os resultados, da análise econômica 
durante 6 anos mostram que a administração de benefícios reduziu o preço médio dos 
medicamentos por dose padrão.
PCV10
ECONOMIC VALUE OF RESTING HEART RATE AS AN INDEPENDENT 
CARDIOVASCULAR RISK FACTOR IN STABLE ANGINA PATIENTS
Félix J, Almeida J
Exigo Consultores, Alhos Vedros, Lisbon, Portugal
OBJECTIVES: Estimate the economic value of heart rate (HR) control in stable angina 
(SA) patients in the perspective of the Brazilian Public Health System (Sistema Único 
de Saúde—SUS). METHODS: A Markov chain Monte Carlo stochastic simulation 
model was used to estimate the inﬂuence of HR in cardiovascular (CV) morbidity and 
mortality and its economic consequences to SUS. Resting HR distribution was mod-
elled as a gamma function. Overall survival and time to hospitalization were modelled 
with weibull survival functions. Only CV events (acute myocardial infarction, stroke, 
heart failure and death) and revascularization procedures (coronary artery bypass graft 
and percutaneous coronary interventions) costs were considered. Brazil’s health 
context was taken into account, including baseline characteristics of SA patients, 
resource utilization and direct costs (no indirect costs were included), reﬂecting SUS 
perspective. Annual discount rate was 5% and time horizon 20 years. RESULTS: 
Reduction in SUS direct costs, per patient, would range from R$147 (95%CI  
[R$136; R$159]) to R$354 (95%CI  [R$321; R$388]) for each 5 bpm decrease in 
HR up to 20 bpm, 70% of these costs reductions resulting from avoidable revascu-
larization procedures. In patients with HR  70 bpm (average HR: 87 bpm), a 10 or 
20 bpm HR reduction would decrease SUS per patient average direct cost by R$404 
(95%CI  [R$393; R$415]) or by R$611 (95%CI  [R$598; R$625]), respectively. 
Only 33% of the 2.5 million Brazilian SA patients take beta-blockers and might 
potentially have the recommended resting HR (50–60 bpm). Thus, a 10 bpm reduction 
